The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
Author:
Affiliation:
1. From the Division of Hematology-Oncology, The Ohio State University, Columbus; Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD; and Burnham Institute, Cancer Research Center, La Jolla, CA.
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/99/3/1038/1680276/1038.pdf
Reference42 articles.
1. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.;Nadler;Cancer Res.,1980
2. Novel therapies for chronic lymphocytic leukemia in the 21st century.;Byrd;Semin Oncol.,2000
3. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.;Davis;J Clin Oncol.,1999
4. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.;McLaughlin;J Clin Oncol.,1998
5. Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.;Maloney;J Clin Oncol.,1998
Cited by 336 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
2. Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
3. Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?;BioDrugs;2023-10-13
4. Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions;Cancers;2023-07-05
5. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3